| The benefit of HER2-targeted therapies on overall survival of patients with metastatic HER2-positive breast cancer–a systematic review D Mendes, C Alves, N Afonso, F Cardoso, JL Passos-Coelho, L Costa, ... Breast Cancer Research 17, 1-14, 2015 | 205 | 2015 |
| Platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma: glutathione S-transferase genetic polymorphisms as predictive biomarkers of disease … R Medeiros, D Pereira, N Afonso, C Palmeira, C Faleiro, C Afonso-Lopes, ... International Journal of Clinical Oncology 8, 156-161, 2003 | 107 | 2003 |
| Chemotherapy de-escalation using an 18F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre … JM Pérez-García, G Gebhart, MR Borrego, A Stradella, B Bermejo, ... The Lancet Oncology 22 (6), 858-871, 2021 | 81 | 2021 |
| Male breast cancer: Looking for better prognostic subgroups MH Abreu, N Afonso, PH Abreu, F Menezes, P Lopes, R Henrique, ... The Breast 26, 18-24, 2016 | 53 | 2016 |
| Occupational risks for uveal melanoma results from a case-control study in nine European countries JM Lutz, I Cree, S Sabroe, TK Kvist, LB Clausen, N Afonso, W Ahrens, ... Cancer Causes & Control 16, 437-447, 2005 | 53 | 2005 |
| Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study … J Gligorov, B Ataseven, M Verrill, M De Laurentiis, KH Jung, HA Azim, ... European Journal of Cancer 82, 237-246, 2017 | 50 | 2017 |
| European multi-centre case–control study on risk factors for rare cancers of unknown aetiology E Lynge, N Afonso, L Kaerlev, J Olsen, S Sabroe, W Ahrens, M Eriksson, ... European Journal of Cancer 41 (4), 601-612, 2005 | 43 | 2005 |
| Perfil da doença oncológica em Portugal racional, objectivos e metodologia-estudo perfil. A Macedo, S Andrade, I Moital, A Moreira, FL Pimentel, S Barroso, J Dinis, ... Acta Médica Portuguesa 21 (4), 329-34, 2008 | 40 | 2008 |
| Pan-European expert meeting on the use of metronomic chemotherapy in advanced breast cancer patients: the PENELOPE project ME Cazzaniga, E Munzone, G Bocci, N Afonso, P Gomez, S Langkjer, ... Advances in Therapy 36, 381-406, 2019 | 33 | 2019 |
| Overall survival prediction for women breast cancer using ensemble methods and incomplete clinical data PH Abreu, H Amaro, DC Silva, P Machado, MH Abreu, N Afonso, ... XIII Mediterranean Conference on Medical and Biological Engineering and …, 2014 | 32 | 2014 |
| Hormonal exposures and the risk of uveal melanoma T Behrens, L Kaerlev, I Cree, JM Lutz, N Afonso, M Eriksson, P Guénel, ... Cancer causes & control 21, 1625-1634, 2010 | 31 | 2010 |
| Chemotherapy (CT) de-escalation using an FDG-PET/CT (F-PET) and pathological response-adapted strategy in HER2 [+] early breast cancer (EBC): PHERGain Trial. J Cortes, G Gebhart, M Ruiz Borrego, A Stradella, B Bermejo, S Escrivá, ... Journal of Clinical Oncology 38 (15_suppl), 503-503, 2020 | 28 | 2020 |
| Occupational exposure to electromagnetic fields and sex-differential risk of uveal melanoma T Behrens, E Lynge, I Cree, S Sabroe, JM Lutz, N Afonso, M Eriksson, ... Occupational and environmental medicine 67 (11), 751-759, 2010 | 25 | 2010 |
| Occupational exposure to organic solvents and risk of male breast cancer: a European multicenter case–control study N Laouali, C Pilorget, D Cyr, M Neri, L Kaerlev, S Sabroe, G Gorini, ... Scandinavian Journal of Work, Environment & Health 44 (3), 312-322, 2018 | 23 | 2018 |
| A randomized phase II trial of ridaforolimus, dalotuzumab, and exemestane compared with ridaforolimus and exemestane in patients with advanced breast cancer HS Rugo, O Trédan, J Ro, SM Morales, M Campone, A Musolino, ... Breast cancer research and treatment 165, 601-609, 2017 | 23 | 2017 |
| Tobacco smoking and alcohol consumption as risk factors for thymoma–A European case-control study M Eriksson, L Kaerlev, P Johansen, N Afonso, W Ahrens, A Costa-Pereira, ... Cancer epidemiology 61, 133-138, 2019 | 21 | 2019 |
| Clinical activity of MCLA-128 (zenocutuzumab), trastuzumab, and vinorelbine in HER2 amplified metastatic breast cancer (MBC) patients (pts) who had progressed on anti-HER2 ADCs. EP Hamilton, T Petit, B Pistilli, A Goncalves, AA Ferreira, F Dalenc, ... Journal of Clinical Oncology 38 (15_suppl), 3093-3093, 2020 | 20 | 2020 |
| Pesticide exposure in farming and forestry and the risk of uveal melanoma T Behrens, E Lynge, I Cree, JM Lutz, M Eriksson, P Guénel, F Merletti, ... Cancer Causes & Control 23, 141-151, 2012 | 20 | 2012 |
| Patterns of recurrence and treatment in male breast cancer: A clue to prognosis? M Henriques Abreu, P Henriques Abreu, N Afonso, D Pereira, R Henrique, ... International Journal of Cancer 139 (8), 1715-1720, 2016 | 19 | 2016 |
| Phase II, multicenter, single-arm trial of eribulin as first-line therapy for patients with aggressive taxane-pretreated HER2-negative metastatic breast cancer: the MERIBEL study V Ortega, A Antón, I Garau, N Afonso, L Calvo, Y Fernández, ... Clinical Breast Cancer 19 (2), 105-112, 2019 | 17 | 2019 |
